Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 trial of MT-110

Next Previous
Trial Profile

Phase 1 trial of MT-110

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 05 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Apr 2025 According to a Myosin Therapeutics media release, company announced that it has been awarded a $3 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). This grant will help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of MT-110.
  • 21 Mar 2023 New trial record
  • 14 Mar 2023 According to a Myosin Therapeutics media release, the company supplemented its National Institutes of Health (NIH) funding with a seed funding round and this capital infusion along with existing funding from the National Institute of Health should provide the funding needed to advance MT-110 through this trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top